Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Esketamine/Neuroimaging & Brain Measures

Esketamine for Neuroimaging & Brain Measures

1 paper and 9 clinical trials exploring esketamine as a treatment for neuroimaging & brain measures.

Compounddissociative

Esketamine

Esketamine (Spravato) is the S-enantiomer of ketamine, approved as an intranasal treatment for treatment-resistant depression and MDD with acute suicidal ideation. It is administered under clinical supervision with post-dose monitoring and has reached over $1.6 billion in annual sales.

Full Esketamine profile
IndicationApproximately 264 million people globally suffer from depression, with PTSD affecting around 8 million adults in the United States each year.

Neuroimaging & Brain Measures

Recent advances in neuroimaging have shed light on the neurobiological mechanisms underlying the effects of psychedelics, particularly in the treatment of mental health disorders such as depression and PTSD. Studies involving compounds like psilocybin and MDMA have demonstrated significant changes in brain activity associated with therapeutic outcomes.

Full Neuroimaging & Brain Measures profile

Academic Research

1 paper
Open Accessmeta

Effects of psychoplastogens on blood levels of brain-derived neurotrophic factor (BDNF) in humans: a systematic review and meta-analysis

This pre-registered systematic review and meta-analysis of 29 studies found no evidence that psychoplastogens (e.g. ketamine, psychedelics, MDMA, scopolamine) acutely increase peripheral BDNF in humans (SMD = 0.024, p = 0.64), with results unchanged by drug, dose, blood fraction, age or diagnosis. The authors conclude peripheral BDNF is unlikely to be a useful marker of rapid neuroplasticity in humans and recommend more precise neuroimaging and stimulation-based measures for future translation.

Published
November 29, 2024
Journal
Molecular Psychiatry
Authors
Calder, A. E., Hase, A., Hasler, G.

Clinical Trials

9 trials
CompletedPhase NA

(GluEsk) Glutamate and Esketamine (GluEsk)

Randomised, double-blind, within-subject crossover study (n=16 actual) assessing single-dose intranasal esketamine 56 mg versus placebo on dynamic brain glutamate release, resting-state connectivity, and vision in healthy volunteers.

Started
June 1, 2024
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT06432322
CompletedPhase NA

Esketamine Treatment for Depressive Episodes With Suicidal Ideation in Mood Disorders

Multicentre, randomised, non-inferiority, parallel-group open-label trial (n=340) comparing six adjunctive IV esketamine infusions (0.2 mg/kg, 40-minute infusion, three times/week) versus six ECT sessions over two weeks for reduction of suicidal ideation in depressive episodes.

Started
April 1, 2024
Type
interventional
Blinding
single
Randomized
Yes
Registry ID
NCT06355180
RecruitingPhase IV

The Anesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury

This randomised, blinded, placebo-controlled, parallel-group pilot and feasibility trial (n=400) will investigate the efficacy and safety of using esketamine for the treatment of patients with severe acute brain injury. It will specifically focus on cortical spreading depolarisations (SDs) in TBI, aSAH, or ICH.

Started
September 15, 2023
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT05095857
Enrolling by invitationPhase NA

Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements (PREDICT)

This observational cohort study (n=540) aims to gather unified data from a large cohort of patients with Major Depressive Disorder (MDD) undergoing various treatment (including ketamine & esketamine) options to identify optimal biomarkers for depression treatments at the individual patient level.

Started
August 14, 2023
Type
observational
Randomized
No
Registry ID
NCT06002100
Completed

Brain Network Dynamics of Depression During Esketamine Treatment

Observational prospective study (n=8 actual enrolled) assessing EEG, pupillometry and belief-updating before and after clinically prescribed esketamine (intranasal 28–84 mg) in people with MDD.

Started
July 3, 2023
Type
observational
Randomized
No
Registry ID
NCT06012916
RecruitingPhase NA

Study of the Neural Circuits Underlying the Negative Emotional Bias of Depressive Disorders and Their Response to Ketamine (EMOKET)

Open-label interventional parallel study (n=96) comparing depressed patients treated with esketamine (Spravato) with healthy volunteers using fMRI emotional tasks, behavioural measures and biological profiling.

Started
March 13, 2023
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06630065

Explore further

Search all Esketamine papers Search all Neuroimaging & Brain Measures trials Full Esketamine profile Full Neuroimaging & Brain Measures profile